Arrhythmias and device therapies in patients with cancer therapy-induced cardiomyopathy

Abstract

Our knowledge of associated cardiotoxicities from novel therapeutics in oncology continues to expand. These include arrhythmias from cancer-therapy induced cardiomyopathy resulting from both direct and indirect effects on cardiomyocytes and other mechanisms that can adversely impact cardiovascular outcomes and overall mortality. In this review, we focus on both the arrhythmias of various classes of oncologic agents as well as the use of cardiac implantable electronic devices (cardioverter-defibrillators, permanent pacemakers, and cardiac resynchronization therapy) in cardio-oncology patients.

Keywords: Arrhythmias; Cancer therapy-induced cardiomyopathy; Cardiac resynchronization therapy; Cardio-oncology; Device therapies.